Tonix Pharmaceuticals Holding Corp

Stock Chart, Company Information, and Scan Results

$44.97(as of Aug 11, 4:00 PM EST)

Stock Market Guides is not a financial advisor. Our content is strictly educational and should not be considered financial advice.

Tonix Pharmaceuticals Holding Corp Company Information, Fundamentals, and Technical Indicators

Stock Price$44.97
Ticker SymbolTNXP
ExchangeNasdaq
SectorHealthcare
IndustryBiotechnology
Employees81
CountyUSA
Market Cap$342.0M
EBIDTA-69.5M
10-Day Moving Average43.66
P/E Ratio-2.09
20-Day Moving Average44.63
Forward P/E Ratio0.00
50-Day Moving Average40.00
Earnings per Share356.28
200-Day Moving Average25.79
Profit Margin-692.84%
RSI57.37
Shares Outstanding7.4M
ATR3.94
52-Week High72.00
Volume694,545
52-Week Low6.76
Most Recent Support Level35.66
Book Value180.4M
Most Recent Resistance Level48.50
P/B Ratio1.53
Upper Keltner53.50
P/S Ratio27.44
Lower Keltner35.76
Debt-to-Equity Ratio53.50
Next Earnings Date11/10/2025
Cash Surplus119.6M
Next Ex-Dividend DateUnknown

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing and commercializing therapeutics to treat and prevent human disease. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults. Its portfolio focuses on central nervous system disorders, as well as immunology, infectious disease, and rare disease product candidates. The company's products pipeline include TNX-102 SL (cyclobenzaprine HCl sublingual tablet), for the management of fibromyalgia; and is being developed to prevent and treat acute stress reaction, posttraumatic stress disorder, Alzheimer's disease, alcohol use disorder, and multi-site pain associated with Long COVID. It also develops TNX-1300, a double-mutant cocaine esterase, which is in Phase 2 clinical trials for the treatment of cocaine intoxication; and TNX-1900, an intranasal potentiated oxytocin for the treatment of binge eating disorder, adolescent obesity, and bone health in pediatric autism, as well as for social anxiety disorder. In addition, the company develops TNX-1500, an Fc-modified humanized monoclonal antibody indicated to prevent organ transplant rejection, as well as to treat autoimmune conditions; TNX-1700, a recombinant Trefoil Factor Family 2 fusion protein for the treatment of gastric and colorectal cancers; TNX-801 that is in the pre-IND development stage for protection against smallpox and mpox; and TNX-1800, a live virus vaccine for SARS-CoV-2. Its rare disease portfolio consists of TNX-2900, an intranasal potentiated oxytocin to treat for Prader-Willi syndrome. The company has collaboration agreement with Bilthoven Biologicals to advance TNX-801 and Makana Therapeutics, Inc. to study TNX-1500 for human-compatible organs and cells for the treatment of organ failure. Tonix Pharmaceuticals Holding Corp. is headquartered in Chatham, New Jersey.

Tonix Pharmaceuticals Holding Corp In Our Stock Scanner

As of Aug 12, 2025
example chart graphic
Scan Name: Cash SurplusScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Uptrending StocksScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Cup and HandleScan Type: Chart Pattern Scans
As of ---
example chart graphic
Scan Name: Low Debt to Equity RatioScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Book ValueScan Type: Stock Fundamentals
As of ---
example chart graphic
Scan Name: Increasing Profit MarginScan Type: Stock Fundamentals
As of ---

Join Our Free Email List

Get emails from us about ways to potentially make money in the stock market.